Literature DB >> 27694923

The calcineurin protein phosphatase is dispensable for BCR-ABL-induced B-ALL maintenance, propagation and response to dasatinib.

F Rocchetti1,2, C Tran Quang1,2, A L Maragno1,2, J Nguyen1,2, C Lasgi3, J Ghysdael1,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27694923     DOI： 10.1038/leu.2016.269

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  13 in total

1.  Calcineurin B1 is essential for positive but not negative selection during thymocyte development.

Authors:  Joel R Neilson; Monte M Winslow; Eun Mi Hur; Gerald R Crabtree
Journal:  Immunity       Date:  2004-03       Impact factor: 31.745

Review 2.  Prolyl cis-trans isomerization as a molecular timer.

Authors:  Kun Ping Lu; Greg Finn; Tae Ho Lee; Linda K Nicholson
Journal:  Nat Chem Biol       Date:  2007-10       Impact factor: 15.040

3.  The src homology 2 domain of Bcr/Abl is required for efficient induction of chronic myeloid leukemia-like disease in mice but not for lymphoid leukemogenesis or activation of phosphatidylinositol 3-kinase.

Authors:  S Roumiantsev; I E de Aos; L Varticovski; R L Ilaria; R A Van Etten
Journal:  Blood       Date:  2001-01-01       Impact factor: 22.113

4.  CXCR4 Is Required for Leukemia-Initiating Cell Activity in T Cell Acute Lymphoblastic Leukemia.

Authors:  Diana Passaro; Marta Irigoyen; Claire Catherinet; Stéphanie Gachet; Cindy Da Costa De Jesus; Charlène Lasgi; Christine Tran Quang; Jacques Ghysdael
Journal:  Cancer Cell       Date:  2015-06-08       Impact factor: 31.743

5.  Acute leukaemia in bcr/abl transgenic mice.

Authors:  N Heisterkamp; G Jenster; J ten Hoeve; D Zovich; P K Pattengale; J Groffen
Journal:  Nature       Date:  1990-03-15       Impact factor: 49.962

6.  Wnt/Ca2+/NFAT signaling maintains survival of Ph+ leukemia cells upon inhibition of Bcr-Abl.

Authors:  Mark A Gregory; Tzu L Phang; Paolo Neviani; Francesca Alvarez-Calderon; Christopher A Eide; Thomas O'Hare; Vadym Zaberezhnyy; Richard T Williams; Brian J Druker; Danilo Perrotti; James Degregori
Journal:  Cancer Cell       Date:  2010-07-13       Impact factor: 31.743

7.  Human structural proteome-wide characterization of Cyclosporine A targets.

Authors:  Gang Hu; Kui Wang; Jody Groenendyk; Khaled Barakat; Marcin J Mizianty; Jishou Ruan; Marek Michalak; Lukasz Kurgan
Journal:  Bioinformatics       Date:  2014-08-28       Impact factor: 6.937

8.  Targeting calcineurin activation as a therapeutic strategy for T-cell acute lymphoblastic leukemia.

Authors:  Hind Medyouf; Hélène Alcalde; Caroline Berthier; Marie Claude Guillemin; Nuno R dos Santos; Anne Janin; Didier Decaudin; Hugues de Thé; Jacques Ghysdael
Journal:  Nat Med       Date:  2007-05-21       Impact factor: 53.440

Review 9.  Current concepts in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia.

Authors:  Kathrin M Bernt; Stephen P Hunger
Journal:  Front Oncol       Date:  2014-03-25       Impact factor: 6.244

Review 10.  The development of dasatinib as a treatment for chronic myeloid leukemia (CML): from initial studies to application in newly diagnosed patients.

Authors:  Andreas Hochhaus; Hagop Kantarjian
Journal:  J Cancer Res Clin Oncol       Date:  2013-08-13       Impact factor: 4.553
View more
  1 in total

1.  IL12 Abrogates Calcineurin-Dependent Immune Evasion during Leukemia Progression.

Authors:  Jennifer L Rabe; Lori Gardner; Rae Hunter; Jairo A Fonseca; Jodi Dougan; Christy M Gearheart; Michael S Leibowitz; Cathy Lee-Miller; Dmitry Baturin; Susan P Fosmire; Susan E Zelasko; Courtney L Jones; Jill E Slansky; Manali Rupji; Bhakti Dwivedi; Curtis J Henry; Christopher C Porter
Journal:  Cancer Res       Date:  2019-05-29       Impact factor: 12.701
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.